CD274 and non-small cell lung carcinoma: The therapeutic landscape of NSCLC has been transformed by ICIs targeting the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4) [3].